Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

NET 1Endocrine 1CNS 1

Conditions

Neuroendocrine Tumors 5Neuroblastoma 2Medulloblastoma 2Carcinoma, Neuroendocrine 2von Hippel-Lindau Disease 1Tumor Positron-Emission Tomography 1Squamous Cell Carcinoma of Head and Neck 1Somatostatinoma 1Prostatic Neoplasms 1Parathyroid Neoplasms 1Multiple Endocrine Neoplasia 1Meningioma 1Hypoglycemia 1Hyperparathyroidism 1Hypercalcemia 1Carcinoid Tumor 1Cancer Diagnosis 1

Interventions

Capecitabine 3Trastuzumab 2Temozolomide 2Sunitinib 2Octreotide 2Leucovorin 2Everolimus 2Bevacizumab 2vatalanib 1tipifarnib 1temsirolimus 1sapanisertib 1regorafenib 1pentetreotide 1pazopanib 1palbociclib 1motesanib diphosphate 1lutetium Lu 177 dotatate 1gallium Ga 68 dotatate 1cixutumumab 1batifiban 1aflibercept 1Thalidomide 1Streptozocin 1Sorafenib 1Sirolimus 1Salts 1Oxaliplatin 1Melphalan 1Magnetic Resonance Spectroscopy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × Somatostatinoma × gallium Ga 68 dotatate × Clear all
NCT01869725 2021-09-22

Comparative Study of Sensitivity of Ga-DOTATOC PET vs Octreoscan SPECT + CT

University of Iowa

Phase 2 Completed
68 enrolled 8 charts
CNSEndocrineNET

Medulloblastoma, Neuroblastoma, Somatostatinoma, Neuroendocrine Tumors

Data powered by HemOnc (CC BY 4.0) Colophon âš¡